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It has been suggested that pediatric acute respiratory distress syndrome (PARDS) may 
be a different entity, vis-à-vis adult acute respiratory distress syndrome (ARDS), based on 
its epidemiology and outcomes. A more pediatric-specific definition of PARDS to include 
the subgroup of patients with underlying lung (and heart) disease has been proposed. 
Epidemiological data suggest that up to 13% of the children with ARDS have a history of 
prematurity and/or underlying chronic lung disease. However, the specific contribution of 
bronchopulmonary dysplasia (BPD), the most common chronic lung disease in infants, 
to the development of PARDS is not known. BPD leads to damaged lungs with long-term 
consequences secondary to disordered growth and immune function. These damaged 
lungs could potentially act as a substrate, which given the appropriate noxious stimuli, 
can predispose a child to PARDS. Interestingly, similar biomarkers [KL-6, interleukin (IL)-
6, IL-8, sICAM-1, angiopoietin-2, and matrix metalloproteinase-8 and -9] of pulmonary 
injury have been associated both with BPD and ARDS. Recognition of a unique pattern 
of clinical symptomatology and/or outcomes of PARDS, if present, could potentially be 
useful for investigating targeted therapeutic interventions.
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iNTRODUCTiON
Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory disease in infants and 
is a devastating condition that disrupts the developmental program of the lung secondary to preterm 
birth. In 2013, one in nine (11.4% of all live births) babies was born at <37 weeks gestation (1). 
Babies born at <32 weeks gestation account for 1.9% of live births, resulting in more than 75,000 
babies admitted to neonatal intensive care units (NICUs) each year (1). Of all births in the US, 1.4% 
(55,548/year) are of very low birth weight (VLBW; <1500 g) infants annually (1), of whom 15,000 
develop BPD (2). In the US, BPD is the leading cause of chronic lung disease in babies and the third 
leading cause in children (2, 3).
Despite many advances in neonatal ventilation techniques, widespread use of surfactant and 
antenatal corticosteroids, the incidence of BPD has remained the same (4) or even increased 
slightly (5, 6). The emotional and financial burden of caring for babies with BPD is significant. 
Babies with BPD require intensive hospital care for an average of 120 days. In 2009, the presence of 
BPD in an infant increased mean direct hospital costs (not including physician fees) in the NICU 
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by ~$60,000 (7). Management of BPD takes a considerable toll 
on health services. Among preterm infants, the single costliest 
complication of hospitalization during infancy is BPD, with an 
average cost per discharge of $116,000 (8). Additionally, BPD is 
associated with significant pulmonary and neurodevelopmental 
sequelae that continue to have health ramifications into adult-
hood (5, 9, 10). Home oxygen therapy, when required, averages 
92 days. Up to 50% of babies with BPD require readmission to the 
hospital for lower respiratory tract illness in the first year of life. 
Median medical costs for home care after discharge is $8100 per 
child; if the child requires hospitalization, the cost increases up 
to $50,000. The overall costs of treating babies with BPD in the 
US are estimated to be $2.4 billion. This amount is second only to 
the costs for treating asthma and far exceeds the costs for treating 
cystic fibrosis.
PATHOGeNeSiS OF BPD
There are five distinct stages in lung development, namely, embry-
onic, pseudoglandular, canalicular, saccular, and alveolar (11, 12). 
Preterm infants who are predisposed to developing BPD are born 
in the late canalicular or early saccular stage of lung development. 
In the late canalicular stage, there is development of the primitive 
alveoli and the alveolar capillary barrier, and the differentiation of 
Type I and Type II pneumocytes (13). In the early saccular stage, 
surfactant production starts along with pulmonary vasculariza-
tion and enlargement of terminal airways (11, 12, 14, 15). The 
lungs complete their development after birth, which continues up 
to 8 years of age (16). Alveolar sacs are formed by secondary sep-
tation of alveolar ducts (13). BPD is caused due to an interaction 
between genetic and environmental factors (hyperoxia, invasive 
mechanical ventilation, and sepsis) (5, 17–19).
The foundation of BPD is the immature lung, which may or 
may not be surfactant deficient. Genetic predisposition probably 
accounts for 50–80% of the susceptibility to BPD (20, 21). The 
genetically predisposed immature lung is exposed to noxious 
external factors: pre- and postnatal infections, hyperoxia, and 
ventilator-induced barotrauma, volutrauma, or atelectotrauma, 
which initiates an inflammatory cascade involving inflammatory 
cells and signaling via various cytokines, chemokines, and growth 
factors. This, in turn, activates the cell death pathways. Damage 
to the developing lung is followed by resolution of injury to close 
to normal lung architecture or repair (19). The “old” or “classical” 
BPD occurred in the pre-surfactant days where invasive ventilation 
practices led to significant lung injury characterized by a severe 
fibroproliferative response along with airway injury and alveolar 
growth abnormalities (22). In the post-surfactant, “gentler” 
ventilation era in the more immature lung, this reparative state 
of the lung is characterized by fewer and larger simplified alveoli, 
along with dysmorphic vasculature, leading to the description of 
impaired alveolarization and dysregulated vascularization – the 
pulmonary phenotype of “new” BPD (5, 18, 22–24).
It is important to highlight the fact that for BPD to occur, it 
requires the known environmental factors to be exposed to the 
immature lung for a sustained duration, resulting in persistent 
inflammation (13). While markers of the early inflammatory 
response (cells, cytokines) may not be detectable after the 
prolonged exposure to the damaging environmental agents, the 
initial cascade of the signaling pathways of the inflammatory pro-
cess/immune response does eventually lead to permanent defects 
of structure and function in the BPD lungs (13). Anatomical and 
functional pulmonary deficits in children and adults who had 
BPD during infancy have been well documented (25–27).
ePiDeMiOLOGY OF PULMONARY 
OUTCOMeS UP TO CHiLDHOOD
High resolution chest CT scans (HRCT) in survivors of old BPD 
and new BPD both show persistent radiological abnormalities 
with structural changes (28–33). The extent of the structural 
abnormality has been found to be associated with abnormal 
pulmonary function tests (28, 30, 31). In younger patients with 
new BPD, Mahut et al. have reported that the extent of structural 
abnormalities is correlated with duration of mechanical ventila-
tion and supplemental oxygen (32).
Structural changes in lungs of BPD survivors based on HRCT 
are more marked in the peripheral lung in both old and new BPD 
survivors (34).
As one would expect, a stormy perinatal period leads to 
lasting effects. Survivors of BPD continue to have a greater 
respiratory morbidity and need for respiratory medications into 
young adulthood. They are also more likely to have chest wall 
deformities and a diagnosis of asthma during childhood (35). 
They have greater rates of hospitalization especially in the first 
2 years of life as compared with infants born full term (36, 37). 
Although rates of hospitalization decrease as these children get 
older, long-term lung function abnormalities persist. Patients 
with old BPD had markedly abnormal lung function during late 
adolescence and 68% of which had evidence of airway obstruc-
tion. There was a marked decrease in forced expiratory volume 
in 1  s (FEV1), forced vital capacity (FVC), and the average 
forced expiratory flow during the mid (25–75%) portion of the 
FVC (FEF 25–75%) with evidence of gas trapping in survivors 
of BPD, as compared with age matched controls who were term 
and preterm infants without BPD (38). In adolescent patients 
(mean age 17.7 years) who were born preterm, Halvorsen et al. 
reported a lower FEV1 when compared those born at term (39). 
Doyle et al. also reported lung function tests of BPD survivors 
at a mean age of 18.9 years. They found a significant decrease 
in FEV1 and FEV1/FVC ratios in patients with a history of 
BPD, compared with those with no BPD (40). Patterns of lung 
function abnormalities were similar in survivors of old and new 
BPD. In patients with new BPD, Fawke et al. found that in over 
half of the cohort of children born at <26 weeks of gestation 
that they followed had abnormal spirometry at 11 years of age 
(35). Others too have reported small airway abnormalities and 
diffusion abnormalities in infants and young children with 
BPD (41–43) and persistent abnormalities into late childhood 
(40, 44–47). BPD survivors with persistent airflow obstruction 
are less likely to respond to bronchodilators as compared with 
patients with asthma with a similar degree of obstruction, 
suggesting that some of the small airway dysfunction seen in 
BPD survivors may be related to structural change rather than 
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eosinophilic inflammation (48). It is difficult to directly com-
pare outcomes in patients with old BPD with new BPD due to 
the lack of conformity in the definition of BPD between the two 
eras since relatively more immature babies are surviving in the 
post-surfactant era as compared with the pre-surfactant era. It 
is important to mention here that, while not the focus of this 
article, significant abnormalities in pulmonary function tests in 
infants with BPD extend well into late adolescence and adult-
hood (31, 38–40, 49–52). On the other hand, in adult survivors 
of acute respiratory distress syndrome (ARDS) (median age 
44 years), pulmonary function has been shown to improve over 
5 years with the majority of patients having normal and near 
normal lung function (53).
Thus, a damaged lung with disordered growth and immune 
function could potentially act as a substrate, given the appropri-
ate noxious stimuli, to predispose a child to ARDS. However, 
until recently, the definitions for ARDS were not well suited for 
children. This may have led to an under diagnosis of ARDS in 
children with underlying lung disease.
ePiDeMiOLOGY OF ARDS/PARDS
When first described by Ashbaugh et al. in the year 1967 (54), adult 
respiratory distress syndrome was defined as respiratory failure 
with the following three criteria, such as (1) PaO2/FiO2 ratio of 
<300 mm of Hg, (2) diffuse bilateral infiltrates on chest radio-
graph, and (3) an identifiable insult within 7 days of developing a 
compromise in oxygenation and a well preserved left ventricular 
function. The terminology of “respiratory distress syndrome” 
was coined as a reference to a similar neonatal condition. In 
1994, recognizing that the adult respiratory distress syndrome 
occurs in both children and adults, the American-European 
Consensus Conference (AECC) changed the nomenclature from 
adult respiratory distress syndrome to acute respiratory distress 
syndrome (ARDS) and defined it as a syndrome of inflamma-
tion and increased permeability in the lungs that is associated 
with a constellation of clinical, radiological, and physiological 
abnormalities that cannot explain but coexist with left atrial or 
pulmonary capillary hypertension (55).
In clinical practice, the adult criteria were used for more than 
a decade in the pediatric population. However, there were limita-
tions in the use of this definition in children, including differences 
in triggering disease states, epidemiology, and outcomes, and 
technical problems of assessing oxygenation in children without 
arterial blood gas measurements. The Berlin definition has 
addressed some of the limitations of the AECC definition (56) 
better, in terms of validity, for predicting mortality with ARDS, 
but still lacked pediatric perspective. Pediatric acute respiratory 
distress syndrome (PARDS) may be a different entity specifically 
based on its epidemiology and outcomes. A group of experts 
have proposed a more pediatric-specific definition of PARDS 
to account for differences in adults and children (57). Authors 
propose the following changes in the (a) simplification of chest 
imaging criteria to eliminate presence of bilateral infiltrates, (b) 
use of pulse oximetry-based criteria when PaO2 is not available, 
and (c) inclusion of oxygenation index instead of PaO2/FiO2 
with a minimum positive end expiratory pressure for invasively 
ventilated patients and specific inclusion of children with under-
lying lung and heart disease.
Pediatric acute respiratory distress syndrome is less common 
as compared with ARDS with an incidence of 2.0–12.8 children 
per 100,000 patient years with a lower morality in PARDS as 
compared with ARDS (58–62). The incidence of PARDS is likely 
underestimated, especially in patients with a preexisting lung 
disease. In a child with underlying lung disease (such as BPD), 
it can be difficult to make a diagnosis of ARDS given the Berlin 
definition. An acutely ill child with underlying lung disease is 
often diagnosed with an exacerbation of their underlying disease 
rather than ARDS, possibly leading to an under diagnosis and 
underestimation of PARDS (59). The revised definition of PARDS 
to specifically include the subgroup of pediatric patients with 
underlying lung and heart disease in the definition of PARDS may 
improve the recognition of this condition.
PATHOGeNeSiS OF ARDS/PARDS
Similar to adults, the most common causes of ARDS in the pedi-
atric age group are underlying pneumonia or viral illness (58, 63). 
Sepsis, aspiration, and trauma can also cause ARDS in children, 
but occur less frequently in children compared with adults. A sig-
nificant proportion of patients of PARDS have underlying chronic 
comorbidities. Of these, underlying chronic lung disease is one 
of the commonest comorbidity reported in pediatric patients 
who develop ARDS/acute lung injury (ALI) (62). Prematurity 
has been reported in 13% of the children with ARDS (45), and 
underlying chronic lung disease has been reported to occur in 
11–13% (62, 63). However, in some studies of ARDS in children, 
patients with underlying hypoxic lung disease were excluded 
(58). Nevertheless, children with BPD are at risk for developing 
ARDS, especially if they have a history of severe BPD that is 
often associated with other comorbidities. These include swallow 
dysfunction and neurodevelopmental delay, which puts them at 
risk for impaired airway clearance and aspiration pneumonia, 
increasing the risk of recurrent pulmonary infections. Therefore, 
it becomes difficult to determine if patients with BPD have a 
flare up of their underlying condition or have ARDS triggered 
by infection, aspiration, or other pulmonary insults. This may 
also affect the management of a patient with acute exacerbation 
of underlying BPD, which may be significantly different from a 
patient with ARDS with underlying BPD; for example, the use 
of corticosteroids would probably be more likely in the former 
category of patients. In addition, pulmonary vascular disease and 
coexistent pulmonary hypertension play a role in the morbidity of 
infants with BPD presenting with respiratory failure. Pulmonary 
vasodilatory therapies, such as inhaled nitric oxide (iNO), may 
help in these circumstances (2). This variability in reported data 
presents challenges in sorting out whether past history of BPD 
increases the risk of development of ARDS or affects outcomes 
in this population.
Despite multiple chronic comorbidities in those with PARDS, 
presence of underlying immunodeficiency is the only comorbid-
ity associated with poor outcome (64, 65). Others have reported 
that non-pulmonary sepsis is associated with increased mortality 
in patients with ALI (62, 65). However, most epidemiological 
TABLe 1 | Biomarkers of lung injury that are similar in BPD and ARDS.
epithelial cells endothelial cells
Angiopoietin-2a Angiopoietin-2a
KL-6 sICAM-1
IL-6
IL-8
MMP-8
MMP-9
aCan be made/released by both epithelial and endothelial cells.
IL, interleukin; MMP, matrix metalloproteinase; sICAM, soluble intercellular adhesion 
molecule.
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studies of ARDS do not list specific diagnoses as comorbidities 
or underlying conditions and, instead, describe organ system 
involvement more broadly. Since BPD is one of the commonest 
forms of preexisting lung disease, it may be reasonable to extrapo-
late that there is no clear associated increase in risk of death with 
PARDS in patients with BPD. However, it is important to clarify 
that there is no specific data to support or refute the extrapolated 
statement.
Some studies have suggested a predominance of Caucasian 
infants being predisposed to BPD (66); this finding has not been 
consistent (67). Given the significant genetic susceptibility to 
BPD, it very likely that if specific single nucleotide polymorphisms 
(SNPs) occur more commonly in a particular race/ethnic group, 
that would be more important for predisposing a particular race/
ethnic group towards developing BPD (68, 69). It is important 
to mention here that race/ethnicity has been noted to impact on 
lung function and utilization of respiratory medications in infants 
born preterm and/or with BPD (70–72). African-American 
adults are more likely to have a more severe disease and greater 
mortality with ARDS. Hispanic adults also have higher mortality 
rates independent of severity of disease (73). There is no reported 
race bias in terms of mortality in PARDS. Male gender has also 
been shown to increase the risk of developing BPD (74, 75). 
However, similar to the data reported in adults with ARDS, in 
PARDS, there is no difference in mortality rates based on gender 
(58, 62, 63, 76, 77).
OUTCOMeS OF PARDS
There is significant mortality associated with PARDS; however, 
these mortality rates appear to be lower than that in adults, rang-
ing from 15 to 50% mortality in children compared with 35 to 
45% mortality in adults (60, 62). There is, however, a wide range 
in the mortality range of the cohorts of children with ARDS (47). 
This wide range in mortality assessment may be due to differences 
in the comorbid or underlying conditions in the children in these 
relatively small cohorts or may be due to improvements in care 
over time (47).
BiOMARKeRS iN BPD AND ARDS
Theoretically, biomarkers can be used to identify at risk population, 
predict severity of illness, target therapy, and predict prognosis.
Various biomarkers detected in different biological fluids have 
been proposed for early identification of infants predisposed to 
BPD (3, 78). The majority of the studies have been conducted 
using blood, urine, or tracheal aspirate (TA) samples (3, 78). 
Among these that have been implicated both in BPD and ARDS 
(vide infra) are the following.
KL-6 (a lung injury marker) was increased in infants in the 
umbilical cord blood samples in infants who went on to develop 
BPD (n = 50 vs. non-BPD n = 24) (79) and was also useful as a 
predictor of moderate/severe BPD at 1 week of postnatal life (80). 
Combining results from all models, BPD/death (n = 606 out of 
1062) was associated with higher levels of interleukin (IL)-6 and 
-8 in blood samples collected at various timepoints during the 
infants’ stay in the NICU (81).
Among the cytokines, it is important to note consistent results 
with increased blood levels of IL-6 and -8 have been associated 
with BPD (3). This is supported by increased concentrations of 
these cytokines in TA obtained from human infants developing 
BPD (3). Among other pulmonary biomarkers of BPD, two 
independent cohorts have reported increased TA levels of angi-
opoietin-2 (Ang-2) to be associated with increased risk of BPD 
and/or death (82, 83).
Soluble intercellular adhesion molecule-1 (sICAM-1) is 
increased in TA samples in the first week of life in infants develop-
ing BPD (77, 84). Increased levels of matrix metalloproteinase 
(MMP)-8 and -9 have been reported in infants developing BPD 
(18, 77, 84).
In a systematic meta-analysis of plasma-derived biomarkers 
associated with ARDS, Terpstra et al. reported ranking of plasma 
biomarkers for ARDS according to the strength of associa-
tion with both diagnosis and mortality of ARDS (85). Authors 
found that KL-6, lactic dehydrogenase, soluble RAGE, and von 
Willebrand factor are strongly associated with the development 
of ARDS in at-risk patients. They also concluded that mortality 
with ARDS was most strongly associated with IL-4, IL-2, Ang-2, 
and KL-6. Increased plasma levels of transferrin and protein C 
were associated with decreased odds for both development of 
ARDS and mortality with ARDS (85). Studies examining the 
role of inflammatory biomarkers in PARDS are far fewer than 
in ARDS (86). Serum IL-8 and IL-6 have both been shown to 
be elevated in patients with PARDS (86). While elevated levels 
of plasma sICAM-1 on days 1 and 2 of ALI were associated with 
increased risk of death and prolonged mechanical ventilation, 
Flori et al. noted that when combined with a physiological index 
of oxygenation defect (PaO2/FiO2), it further strengthened the 
predicted value risk of death in PARDS (87). Higher TA MMP-8 
and MMP-9 levels in patients with PARDS have been shown to 
correlate with increased risk of death and prolonged mechanical 
ventilation (87, 88). The biomarkers have been categorized into 
markers of pulmonary epithelial or endothelial ling injury and 
summarized in Table 1.
It is unclear what causes the difference in outcomes of pedi-
atric patients, as compared with adults with ARDS. It has been 
suggested that in pediatric patients the stage of lung development 
at the time of the insult may be one cause of this outcome differ-
ence. This may pertain especially to younger children. It is known 
that alveolar development is a primarily postnatal process which 
starts at ~36 weeks of gestation and continues in the postnatal 
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period. Maximal alveolar growth is completed by 24 months of 
age, although there may be some growth that occurs for up to 
8 years. Although this has not been researched adequately, in a 
child where alveolar growth is still not complete, ARDS may lead 
to a different pathology, thus affecting not only the course of the 
disease but also the long-term outcome.
Acute respiratory distress syndrome is primarily an inflamma-
tory response to injury. There is evidence to suggest that children 
have a unique inflammatory response to injury, which confers 
protection from development of multi-organ failure, although 
underlying mechanisms are not known (89). It is fair to say that 
the child’s inherent immune response may have some role to play 
in the difference in the course and outcomes of PARDS.
LACK OF DATA AND NeeD FOR  
FUTURe ReSeARCH
Pediatric acute respiratory distress syndrome is less common 
than ARDS; furthermore, epidemiological studies of PARDS do 
not provide specific diagnoses as comorbidities or underlying 
conditions. This limits our understanding of how underlying 
lung disease (specifically BPD) may affect the pattern of clini-
cal presentation and/or outcomes of PARDS. Newer criteria of 
PARDS have been proposed recently, which we hope will help 
better understand the contribution of underlying chronic lung 
disease to PARDS. Proper categorization and definition of 
ARDS in patients with underlying disease, such as BPD, are also 
important to guide clinical therapy. This review highlights many 
questions that remain unanswered and underscores the need for 
future multidisciplinary collaboration to study the long-term 
outcome of BPD and as a substrate for PARDS.
SUMMARY AND CONCLUSiON
Chronic pulmonary disease is a commonly seen comorbidity in 
patients with PARDS. There is no clear data to suggest an associa-
tion of BPD with increased probability of developing ARDS, nei-
ther is there any suggestion that underlying lung disease portends 
a worse outcome with ARDS. However, similar biomarkers (KL-6, 
IL-6, IL-8, sICAM-1, Ang-2, and MMP-8 and -9) of pulmonary 
injury have been associated both with BPD and ARDS. Current 
practice where pediatric patients are more likely to be diagnosed 
with their underlying disease rather than PARDS underestimates 
the true incidence of ARDS, and possibly the effect of underlying 
chronic lung disease. Future research incorporating listing BPD 
as a specific underlying diagnosis would assist in recognition of 
a unique pattern (if present) of clinical presentation and/or out-
comes of PARDS, which, in turn, could potentially set the stage 
for investigating targeted therapeutic interventions.
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